Cell‑free DNA as a liquid biopsy for early detection of gastric cancer (Review)
- Authors:
- Zheng-Bin Huang
- Hai-Tao Zhang
- Benjamin Yu
- De-Hua Yu
-
Affiliations: Department of Surgery, Hanchuan Renmin Hospital, Hanchuan, Hubei 431600, P.R. China, Department of Gastrointestinal Surgery, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518037, P.R. China, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA, Shenzhen USK Bioscience Co., Ltd., Shenzhen, Guangdong 518110, P.R. China - Published online on: November 3, 2020 https://doi.org/10.3892/ol.2020.12264
- Article Number: 3
-
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi T, Saikawa Y and Kitagawa Y: Gastric cancer: Current status of diagnosis and treatment. Cancers (Basel). 5:48–63. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rosati G, Ferrara D and Manzione L: New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol. 15:2689–2692. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H and Sobue T: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 38:259–267. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Choi KS, Jun JK, Lee HY, Park S, Jung KW, Han MA, Choi IJ and Park EC: Performance of gastric cancer screening by endoscopy testing through the national cancer screening program of Korea. Cancer Sci. 102:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al: Screening for gastric cancer in Asia: Current evidence and practice. Lancet Oncol. 9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Figueroa LS, Halperin D and Parsonnet J: Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev. 10:107–112. 2001.PubMed/NCBI | |
|
Katai H and Sano T: Early gastric cancer: Concepts, diagnosis, and management. Int J Clin Oncol. 10:375–383. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tashiro A, Sano M, Kinameri K, Fujita K and Takeuchi Y: Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol. 12:4873–4874. 2006.PubMed/NCBI | |
|
Tonouchi H, Mohri Y, Kobayashi M, Tanaka K, Ohi M and Kusunoki M: Laparoscopy-assisted distal gastrectomy with laparoscopic sentinel lymph node biopsy after endoscopic mucosal resection for early gastric cancer. Surg Endosc. 21:1289–1293. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kusano C, Iwasaki M, Kaltenbach T, Conlin A, Oda I and Gotoda T: Should elderly patients undergo additional surgery after non-curative endoscopic resection for early gastric cancer? Long-term comparative outcomes. Am J Gastroenterol. 106:1064–1069. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
ASGE Standards of Practice Committee, ; Ben-Menachem T, Decker GA, Early DS, Evans J, Fanelli RD, Fisher DA, Fisher L, Fukami N, Hwang JH, et al: Adverse events of upper GI endoscopy. Gastrointest Endosc. 76:707–718. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M and Ichinose M: Serum Pepsinogen and Gastric Cancer Screening. Intern Med. 46:261–266. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, Matsushima T and Takahashi K: Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn. 22:133–141. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Shakeri R, Persson EC, Islami F, Kamangar F, Abnet CC, Boffetta P, Engstrand L, et al: Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: Influence of gastritis. PLoS One. 6:e269572011. View Article : Google Scholar : PubMed/NCBI | |
|
Miki K and Urita Y: Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 8:8–14. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB and Yan C: Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: A systematic review and meta-analysis. PLoS One. 10:e01420802015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Ma X, Bi F and Liu M: Clinical significance of circulating tumor cells in gastric cancer patients. Oncotarget. 8:25713–25720. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Ling Y, Qi Q, Lan F, Zhu M, Zhang Y, Bao Y and Zhang C: Prognostic value of circulating tumor cells in advanced gastric cancer patients receiving chemotherapy. Mol Clin Oncol. 6:235–242. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
De Mattos-Arruda L, Olmos D and Tabernero J: Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer. Future Oncol. 7:1385–1397. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shapiro B, Chakrabarty M, Cohn EM and Leon SA: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 51:2116–2120. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Sai S, Ichikawa D, Tomita H, Ikoma D, Tani N, Ikoma H, Kikuchi S, Fujiwara H, Ueda Y and Otsuji E: Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res. 27:2747–2751. 2007.PubMed/NCBI | |
|
Park JL, Kim HJ, Choi BY, Lee HC, Jang HR, Song KS, Noh SM, Kim SY, Han DS and Kim YS: Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett. 3:921–926. 2012.PubMed/NCBI | |
|
Kim K, Shin DG, Park MK, Baik SH, Kim TH, Kim S and Lee S: Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: Diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 86:136–142. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Qian C, Ju S, Qi J, Zhao J, Shen X, Jing R, Yu J, Li L, Shi Y, Zhang L, et al: Alu-based cell-free DNA: A novel biomarker for screening of gastric cancer. Oncotarget. 8:54037–54045. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kolesnikova EV, Tamkovich SN, Bryzgunova OE, Shelestyuk PI, Permyakova VI, Vlassov VV, Tuzikov AS, Laktionov PP and Rykova EY: Circulating DNA in the blood of gastric cancer patients. Ann N Y Acad Sci. 1137:226–231. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Coimbra S, Catarino C, Costa E, Oliveira H, Figueiredo A, Rocha-Pereira P and Santos-Silva A: Circulating cell-free DNA levels in Portuguese patients with psoriasis vulgaris according to severity and therapy. Br J Dermatol. 170:939–942. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Shi C, Huang X, Zheng J, Zhu Z, Li Q, Qiu S, Huang Z, Zhuang Z, Wu R, et al: Molecular profiles and metastasis markers in Chinese patients with gastric carcinoma. Sci Rep. 9:139952019. View Article : Google Scholar : PubMed/NCBI | |
|
Wu R, Li Q, Wu F, Shi C and Chen Q: Comprehensive analysis of CDC27 related to peritoneal metastasis by whole exome sequencing in gastric cancer. Onco Targets Ther. 13:3335–3346. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, et al: Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut. 69:18–31. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI | |
|
Chen K, Zhao H, Yang F, Hui B, Wang T, Wang LT, Shi Y and Wang J: Dynamic changes of circulating tumour DNA in surgical lung cancer patients: Protocol for a prospective observational study. BMJ Open. 8:e0190122018. View Article : Google Scholar : PubMed/NCBI | |
|
Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, et al: RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: The AGEO RASANC prospective multicenter study. Ann Oncol. 29:1211–1219. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, et al: Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 359:926–930. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 61:673–684. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Qian Z, Zhu G, Tang L, Wang M, Zhang L, Fu J, Huang C, Fan S, Sun Y, Lv J, et al: Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. Genes Chromosomes Cancer. 53:883–894. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Park KU, Lee HE, Park DJ, Jung EJ, Song J, Kim HH, Choe G, Kim WH and Lee HS: MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med. 47:530–536. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Park KU, Lee HE, Nam SK, Nam KH, Park DJ, Kim HH, Kim WH and Lee HS: The quantification of HER2 and MYC gene fragments in cell-free plasma as putative biomarkers for gastric cancer diagnosis. Clin Chem Lab Med. 52:1033–1040. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kinugasa H, Nouso K, Tanaka T, Miyahara K, Morimoto Y, Dohi C, Matsubara T, Okada H and Yamamoto K: Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer. 112:1652–1655. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Komatsu S, Shiozaki A, et al: Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer. 20:126–135. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Taby R and Issa JP: Cancer epigenetics. CA Cancer J Clin. 60:376–392. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Xu H, Su S, Ye J, Chen J, Jin X, Lin Q, Zhang D, Ye C and Chen C: Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS One. 12:e01833312017. View Article : Google Scholar : PubMed/NCBI | |
|
Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res. 72:141–196. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PA and Laird PW: Cancer-epigenetics comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Ebrahimi V, Soleimanian A, Ebrahimi T, Azargun R, Yazdani P, Eyvazi S and Tarhriz V: Epigenetic modifications in gastric cancer: Focus on DNA methylation. Gene. 742:1445772020. View Article : Google Scholar : PubMed/NCBI | |
|
Eyvazi S, Khamaneh AM, Tarhriz V, Bandehpour M, Hejazi MS, Sadat ATE and Sepehri B: CpG islands methylation analysis of CDH11, EphA5, and HS3ST2 genes in gastric adenocarcinoma patients. J Gastrointest Cancer. 51:579–583. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Donaldson J and Park BH: Circulating tumor DNA: Measurement and clinical utility. Annu Rev Med. 69:223–234. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Gole J, Gore A, He Q, Lu M, Min J, Yuan Z, Yang X, Jiang Y, Zhang T, et al: Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun. 11:34752020. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang P, Chan KCA and Lo YMD: Liver-derived cell-free nucleic acids in plasma: Biology and applications in liquid biopsies. J Hepatol. 71:409–421. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, Oxnard GR, Klein EA, Smith D, Richards D, et al: Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 31:745–759. 2020. View Article : Google Scholar | |
|
U.S. Food and Drug Administration (FDA), . Premarket Approval (PMA) for Epi ProColon. FDA; Silver Spring, MD: 2016 | |
|
Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D and Plass C: Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res. 68:4494–4499. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kreuziger LM, Porcher JC, Ketterling RP and Steensma DP: An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. Leuk Res. 31:1145–1148. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Shirley M: Epi proColon® for colorectal cancer screening: A profile of its use in the USA. Mol Diagn Ther. 24:497–503. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, et al: Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 63:317–325. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nian J, Sun X, Ming S, Yan C, Ma Y, Feng Y, Yang L, Yu M, Zhang G and Wang X: Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: A systematic review and meta-analysis. Clin Transl Gastroenterol. 8:e2162017. View Article : Google Scholar : PubMed/NCBI | |
|
Cai L, Hood S, Kallam E, Overman D, Barker K, Rutledge D, Riojas J, Best C, Eisenberg M and Kam-Morgan L: Epi proColon®: Use of a non-invasive SEPT9 gene methylation blood test for colorectal cancer screening: A national laboratory experience. J Clin Epigenet. 4:72018. View Article : Google Scholar | |
|
Sherr CJ: The pezcoller lecture: Cancer cell cycles revisited. Cancer Res. 60:3689–3695. 2000.PubMed/NCBI | |
|
Weisenberger DJ: Characterizing DNA methylation alterations from the cancer genome atlas. J Clin Invest. 124:17–23. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kanyama Y, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S and Nakao A: Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci. 94:418–420. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ichikawa D, Koike H, Ikoma H, Ikoma D, Tani N, Otsuji E, Kitamura K and Yamagishi H: Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res. 24:2477–2481. 2004.PubMed/NCBI | |
|
Guo L, Huang C and Ji QJ: Aberrant promoter hypermethylation of p16, survivin, and retinoblastoma in gastric cancer. Bratisl Lek Listy. 118:164–168. 2017.PubMed/NCBI | |
|
Abbaszadegan MR, Moaven O, Sima HR, Ghafarzadegan K, A'Rabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M, Esmaili-Shandiz E and Dadkhah E: p16 promoter hypermethylation: A useful serum marker for early detection of gastric cancer. World J Gastroenterol. 14:2055–2060. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen F, Liu X, Bai J, Pei D and Zheng J: The emerging role of RUNX3 in cancer metastasis (Review). Oncol Rep. 35:1227–1236. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ and Kang GH: Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 84:479–484. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sakakura C, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, et al: Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res. 29:2619–2625. 2009.PubMed/NCBI | |
|
Lu XX, Yu JL, Ying LS, Han J, Wang S, Yu QM, Wang XB, Fang XH and Ling ZQ: Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer. 118:5507–5517. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Z, Luo M, Chen X, He X, Qian Y, Lai S, Si J and Chen S: Combined detection of plasma ZIC1, HOXD10 and RUNX3 methylation is a promising strategy for early detection of gastric cancer and precancerous lesions. J Cancer. 8:1038–1044. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shi DT, Han M, Gao N, Tian W and Chen W: Association of RASSF1A promoter methylation with gastric cancer risk: A meta-analysis. Tumour Biol. 35:943–948. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, et al: Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 14:3074–3080. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, et al: Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutat Res. 778:46–51. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pimson C, Ekalaksananan T, Pientong C, Promthet S, Putthanachote N, Suwanrungruang K and Wiangnon S: Aberrant methylation of PCDH10 and RASSF1A genes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer. PeerJ. 4:e21122016. View Article : Google Scholar : PubMed/NCBI | |
|
Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N and Taniguchi T: Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem. 275:22627–22630. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H and Watanabe M: DNA damage-inducible gene, Reprimo functions as a tumor-suppressor and is suppressed by promoter methylation in gastric cancer. Mol Cancer Res. 11:1362–1374. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bernal C, Aguayo F, Villarroel C, Vargas M, Díaz I, Ossandon FJ, Santibáñez E, Palma M, Aravena E, Barrientos C and Corvalan AH: Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res. 14:6264–6269. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu L and Yang X: Implication of Reprimo and hMLH1 gene methylation in early diagnosis of gastric carcinoma. Int J Clin Exp Pathol. 8:14977–14982. 2015.PubMed/NCBI | |
|
Lai J, Wang H, Luo Q, Huang S, Lin S, Zheng Y and Chen Q: The relationship between DNA methylation and Reprimo gene expression in gastric cancer cells. Oncotarget. 8:108610–108623. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hu W, Zheng W, Liu Q, Chu H, Chen S, Kim JJ, Wu J and Si J: Diagnostic accuracy of DNA methylation in detection of gastric cancer: A meta-analysis. Oncotarget. 8:113142–113152. 2015. View Article : Google Scholar | |
|
Chen X, Lin Z, Xue M, Si J and Chen S: Zic1 promoter hypermethylation in plasma DNA is a potential biomarker for gastric cancer and intraepithelial neoplasia. PLoS One. 10:e01339062015. View Article : Google Scholar : PubMed/NCBI | |
|
Xue WJ, Feng Y, Wang F, Li P, Liu YF, Guo YB, Wang ZW and Mao QS: The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer. Tumour Biol. 37:11249–11257. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung KF, Lam CN, Wu K, Ng EK, Chong WW, Cheng AS, To KF, Fan D, Sung JJ and Yu J: Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer. 118:947–959. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Li N, Lu H, Wang Z, Chen C, Wu L, Liu J, Lu Y and Wang F: Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal square cell carcinoma. Biomed Rep. 3:123–127. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
epigenomics: Epigenomics AG gets CE-IVD Mark for Lung Cancer Test Epi proLung(R). 2017. | |
|
Powrózek T, Krawczyk P, Kucharczyk T and Milanowski J: Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: Preliminary report. Med Oncol. 31:9172014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HS, Hwang SM, Kim TS, Kim DW, Park DJ, Kang SB, Kim HH and Park KU: Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. Transl Oncol. 6:290–296. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, et al: Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci USA. 113:E1826–E1834. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Snyder MW, Kircher M, Hill AJ, Daza RM and Shendure J: Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 164:57–68. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, Grimes B, Krysan K, Yu M, Wang W, et al: CancerLocator: Non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. Genome Biol. 18:532017. View Article : Google Scholar : PubMed/NCBI | |
|
Guo S, Diep D, Plongthongkum N, Fung HL and Zhang K and Zhang K: Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet. 49:635–642. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N: Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Heitzer E, Haque IS, Roberts CES and Speicher MR: Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 20:71–88. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Leung F, Kulasingam V, Diamandis EP, Hoon DS, Kinzler K, Pantel K and Alix-Panabières C: Circulating tumor DNA as a cancer biomarker: Fact or fiction? Clin Chem. 62:1054–1060. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bartels S, Persing S, Hasemeier B, Schipper E, Kreipe H and Lehmann U: Molecular analysis of circulating cell-free DNA from lung cancer patients in routine laboratory practice: A cross-platform comparison of three different molecular methods for mutation detection. J Mol Diagn. 19:722–732. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wan R, Wang Z, Lee JJ, Wang S, Li Q, Tang F, Wang J, Sun Y, Bai H, Wang D, et al: Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small cell lung cancer. J Thorac Oncol. 12:1376–1387. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J, et al: Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 61:974–982. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, Chaperot L, Leccia MT, Coll JL, Hurbin A, et al: Plasma circulating tumor DNA levels for the monitoring of melanoma patients: Landscape of available technologies and clinical applications. Biomed Res Int. 2017:59861292017. View Article : Google Scholar : PubMed/NCBI | |
|
Rachiglio AM, Esposito Abate R, Sacco A, Pasquale R, Fenizia F, Lambiase M, Morabito A, Montanino A, Rocco G, Romano C, et al: Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Oncotarget. 7:66595–66605. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen W, Ye H, Liu JH, Wei S, Zhao MY, et al: Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 370:324–331. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, et al: Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 34:547–555. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, et al: Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 9:eaan24152017. View Article : Google Scholar : PubMed/NCBI | |
|
Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, et al: Rapid identification of plasma DNA samples with increased ctDNA levels by a modified FAST-SeqS approach. Clin Chem. 61:838–849. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kinde I, Wu J, Papadopoulos N, Kinzler KW and Vogelstein B: Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 108:9530–9535. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhai J, Wu Y, Luo X, Li X and Yu DH: Abstract 643: An ultra-sensitive multiplex allele-specific real-time PCR (Udx-PCR) assay for detection of KRAS BRAF NRAS mutations in colorectal cancer. Cancer Res. 78:6432018. | |
|
Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, et al: Analysis of plasma epstein-barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 377:513–522. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Fiala C and Diamandis EP: Can Grail find the trail to early cancer detection? Clin Chem Lab Med. 57:403–406. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu YH, Zhang LH, Ren H, Zhang GG, Qin F, Kong GZ, Deng GR and Ji JF: Promoter hypermethylation of p16 gene in pre- and post-operative plasma of patients with gastric adenocarcinoma. Beijing Da Xue Xue Bao Yi Xue Ban. 37:257–260. 2005.(In Chinese). PubMed/NCBI | |
|
Koike H, Ichikawa D, Ikoma H, Otsuji E, Kitamura K and Yamagishi H: Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol. 87:182–186. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Guo X, Liu W, Pan Y, Ni P, Ji J, Guo L, Zhang J, Wu J, Jiang J, Chen X, et al: Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. Oncogene. 29:3908–3920. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng Y, Chen L, Li J, Yu B, Su L, Chen X, Yu Y, Yan M, Liu B and Zhu Z: Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis. Clin Biochem. 44:1405–1411. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ng EK, Leung CP, Shin VY, Wong CL, Ma ES, Jin HC, Chu KM and Kwong A: Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One. 6:e222332011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Su L, Li J, Zheng Y, Yu B, Yu Y, Yan M, Gu Q, Zhu Z and Liu B: Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis Markers. 32:195–202. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Raja UM, Gopal G and Rajkumar T: Intragenic DNA methylation concomitant with repression of ATP4B and ATP4A gene expression in gastric cancer is a potential serum biomarker. Asian Pac J Cancer Prev. 13:5563–5568. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S and Wu YC: Circulating methylated XAF1 DNA indicates poor prognosis for gastric cancer. PLoS One. 8:e671952013. View Article : Google Scholar : PubMed/NCBI | |
|
Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, et al: Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin Chem Lab Med. 51:1505–1510. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Song Y, Xia P, Cheng Y, Guo Q, Diao D, Wang W, Wu X, Liu D and Dang C: Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer. Med Oncol. 31:8302014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang G, Zhang W, Zhou B, Jin C, Wang Z, Yang Y, Wang Z, Chen Y and Feng X: The diagnosis value of promoter methylation of UCHL1 in the serum for progression of gastric cancer. Biomed Res Int. 2015:7410302015. View Article : Google Scholar : PubMed/NCBI | |
|
Li WH, Zhou ZJ, Huang TH, Guo K, Chen W, Wang Y, Zhang H, Song YC and Chang DM: Detection of OSR2, VAV3, and PPFIA3 methylation in the serum of patients with gastric cancer. Dis Markers. 2016:57805382016. View Article : Google Scholar : PubMed/NCBI | |
|
Hu H, Chen X, Wang C, Jiang Y, Li J, Ying X, Yang Y, Li B, Zhou C, Zhong J, et al: The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer. Oncotarget. 8:84054–84065. 2017. View Article : Google Scholar : PubMed/NCBI |
